Stanley B Pounds

List of Publications by Year in Descending Order

199 papers	14,597 citations	57 h-index	119 g-index
222 ext. papers	17,330 ext. citations	9 avg, IF	5.74 L-index

#	Paper	IF	Citations
199	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.. *Journal of Clinical Oncology*, **2022**, JCO2101422	2.2	2
198	Phase Separation mediates NUP98 Fusion Oncoprotein Leukemic Transformation.. *Cancer Discovery* , **2021**,	24.4	6
197	Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis. *Blood*, **2021**, 138, 2295-2295	2.2	
196	Gene-set distance analysis (GSDA): a powerful tool for gene-set association analysis. *BMC Bioinformatics*, **2021**, 22, 207	3.6	
195	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. *Blood*, **2021**, 138, 948-958	2.2	7
194	Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML. *Frontiers in Oncology*, **2021**, 11, 678008	5.3	2
193	DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. *Clinical and Translational Science*, **2021**, 14, 137-142	4.9	6
192	SequencErr: measuring and suppressing sequencer errors in next-generation sequencing data. *Genome Biology*, **2021**, 22, 37	18.3	3
191	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. *Nature Cancer*, **2021**, 2, 284-299	15.4	19
190	The Common Germline Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. *Cancer Research*, **2021**, 81, 2442-2456	10.1	2
189	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. *Nature Communications*, **2021**, 12, 985	17.4	9
188	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. *Blood Cancer Discovery*, **2021**, 2, 586-599	7	0
187	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. *Lancet Oncology, The*, **2020**, 21, 551-560	21.7	34
186	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. *Nature Cancer*, **2020**, 1, 329-344	15.4	19
185	Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. *Blood Cancer Discovery*, **2020**, 1, 96-111	7	44
184	Pharmacogenomics of intracellular methotrexate polyglutamates in patientsSleukemia cells in vivo. *Journal of Clinical Investigation*, **2020**, 130, 6600-6615	15.9	6
183	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. *Leukemia*, **2020**, 34, 735-745	10.7	14

182	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. *Clinical Cancer Research*, **2019**, 25, 7320-7330	12.9	10
181	Bacterial Factors Required for Transmission of Streptococcus pneumoniae in Mammalian Hosts. *Cell Host and Microbe*, **2019**, 25, 884-891.e6	23.4	23
180	MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia. *Genes*, **2019**, 10,	4.2	2
179	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia **2019**, 7, 81		46
178	Genomic subtyping and therapeutic targeting of acute erythroleukemia. *Nature Genetics*, **2019**, 51, 694-704	30.3	54
177	H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. *Acta Neuropathologica*, **2019**, 137, 637-655	14.3	43
176	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML. *Clinical and Translational Science*, **2019**, 12, 641-647	4.9	5
175	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. *Journal of Clinical Oncology*, **2019**, 37, 2072-2081	2.2	14
174	Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses. *Blood*, **2019**, 134, 918-918	2.2	0
173	Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes. *Blood*, **2019**, 134, LBA-4-LBA-4	2.2	20
172	OR02-1 DNA Methylation Profiling in Pediatric Adrenocortical Tumors Reveals Distinct Methylation Signatures with Prognostic Significance: A Report from the International Pediatric Adrenocortical Tumor Registry. *Journal of the Endocrine Society*, **2019**, 3,	0.4	78
171	SAT-LB058 Effect of a Genetic Modifier of Cancer Risk in TP53 Mutation Carriers. *Journal of the Endocrine Society*, **2019**, 3,	0.4	78
170	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. *Blood*, **2019**, 134, 178-178	2.2	
169	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 649-649	2.2	2
168	A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome. *Blood*, **2019**, 134, 1429-1429	2.2	
167	Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. *Nature Communications*, **2019**, 10, 5806	17.4	7
166	DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry. *JCO Precision Oncology*, **2019**, 3,	3.6	4
165	Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. *Cancer Cell*, **2019**, 35, 140-155.e7	24.3	109

164	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. *Nature Genetics*, **2019**, 51, 296-307	36.3	189
163	Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia. *Clinical Infectious Diseases*, **2018**, 67, 541-548	11.6	57
162	Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. *Nature*, **2018**, 555, 371-376	50.4	380
161	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. *Acta Neuropathologica*, **2018**, 136, 315-326	14.3	19
160	Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts. *Brain Pathology*, **2018**, 28, 112-120	6	20
159	Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. *Pharmacogenomics*, **2018**, 19, 1101-1110	2.6	5
158	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. *Acta Neuropathologica*, **2018**, 136, 211-226	14.3	111
157	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. *Journal of Clinical Investigation*, **2018**, 128, 369-380	15.9	25
156	Metabolomics Profiling Reveals Markers for Chemosensitivity and Clinical Outcomes in Pediatric AML Patients. *Blood*, **2018**, 132, 1536-1536	2.2	3
155	Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. *Oncotarget*, **2018**, 9, 26711-26723	3.3	19
154	Genome-wide association analysis identifies SNPs predictive of leukemic cell sensitivity to cytarabine in pediatric AML. *Oncotarget*, **2018**, 9, 34859-34875	3.3	6
153	Pediatric LSC3 (pLSC3) Score Derived from DNMT3B-CD34-GPR56 As a Prognostic Tool to Predict AML Patient Outcome: Results from Two Independent Pediatric AML Cohorts. *Blood*, **2018**, 132, 290-290	2.2	
152	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 565-565	2.2	1
151	Integrated Genome Wide Association Study (GWAS) Identifies SNPs Associated with Outcome in Pediatric AML. *Blood*, **2018**, 132, 2758-2758	2.2	2
150	The genetic basis and cell of origin of mixed phenotype acute leukaemia. *Nature*, **2018**, 562, 373-379	50.4	140
149	POST: A framework for set-based association analysis in high-dimensional data. *Methods*, **2018**, 145, 76-84	4.6	1
148	Statistical selection of biological models for genome-wide association analyses. *Methods*, **2018**, 145, 67-75	4.6	3
147	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. *Leukemia and Lymphoma*, **2017**, 58, 247-250	1.9	4

146	A Robust and Powerful Set-Valued Approach to Rare Variant Association Analyses of Secondary Traits in Case-Control Sequencing Studies. *Genetics*, **2017**, 205, 1049-1062	4	3
145	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. *Cancer Research*, **2017**, 77, 2102-2111	10.1	30
144	MLF1 is a proapoptotic antagonist of HOP complex-mediated survival. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2017**, 1864, 719-727	4.9	4
143	High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. *Journal of Clinical Oncology*, **2017**, 35, 394-401	2.2	227
142	Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. *Cancer*, **2017**, 123, 3791-3798	6.4	22
141	Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors. *Cancer*, **2017**, 123, 3150-3158	6.4	18
140	Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children$s Oncology Group Study. *Journal of Clinical Oncology*, **2017**, 35, 3956-3963	2.2	22
139	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nature Genetics*, **2017**, 49, 1211-1218	36.3	430
138	Clinical significance of in vivo cytarabine-induced gene expression signature in AML. *Leukemia and Lymphoma*, **2016**, 57, 909-20	1.9	5
137	Comparative Performance of Reagents and Platforms for Quantitation of Cytomegalovirus DNA by Digital PCR. *Journal of Clinical Microbiology*, **2016**, 54, 2602-8	9.7	21
136	Multi-organ Mapping of Cancer Risk. *Cell*, **2016**, 166, 1132-1146.e7	56.2	83
135	TERT promoter mutations and prognosis in solitary fibrous tumor. *Modern Pathology*, **2016**, 29, 1511-1522	5.8	57
134	Rapid Antimicrobial Susceptibility Testing Using Forward Laser Light Scatter Technology. *Journal of Clinical Microbiology*, **2016**, 54, 2701-2706	9.7	33
133	The genomic landscape of core-binding factor acute myeloid leukemias. *Nature Genetics*, **2016**, 48, 1551-1556	36.3	147
132	CC-PROMISE effectively integrates two forms of molecular data with multiple biologically related endpoints. *BMC Bioinformatics*, **2016**, 17, 382	3.6	3
131	Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children$s Oncology Group Study. *Clinical Cancer Research*, **2016**, 22, 6247-6255	12.9	18
130	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. *Clinical Pharmacology and Therapeutics*, **2016**, 99, 651-60	6.1	19
129	Comparative evaluation of whole blood versus plasma for quantitative detection of cytomegalovirus using an automated system. *Diagnostic Microbiology and Infectious Disease*, **2016**, 85, 23-5	2.9	6

128	Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. *Acta Neuropathologica*, **2016**, 131, 299-307	14.3	32
127	The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. *Blood*, **2016**, 128, 39-39	2.2	2
126	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. *Blood*, **2016**, 128, 454-454	2.2	3
125	Linking Subclonal Genetic Diversity with Functional Heterogeneity Identifies Diagnosis Subclones Destined to Relapse. *Blood*, **2016**, 128, 605-605	2.2	
124	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. *Blood*, **2016**, 128, 2838-2838	2.2	
123	Higher-order oligomerization promotes localization of SPOP to liquid nuclear speckles. *EMBO Journal*, **2016**, 35, 1254-75	13	113
122	Quantitative Assessment of Commutability for Clinical Viral Load Testing Using a Digital PCR-Based Reference Standard. *Journal of Clinical Microbiology*, **2016**, 54, 1616-1623	9.7	13
121	Comparative Evaluation of Four Real-Time PCR Methods for the Quantitative Detection of Epstein-Barr Virus from Whole Blood Specimens. *Journal of Molecular Diagnostics*, **2016**, 18, 527-34	5.1	10
120	The genomic landscape of childhood and adolescent melanoma. *Journal of Investigative Dermatology*, **2015**, 135, 816-823	4.3	121
119	Comparative evaluation of three commercial quantitative cytomegalovirus standards by use of digital and real-time PCR. *Journal of Clinical Microbiology*, **2015**, 53, 1500-5	9.7	31
118	Genomic landscape of paediatric adrenocortical tumours. *Nature Communications*, **2015**, 6, 6302	17.4	116
117	The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. *Nature Genetics*, **2015**, 47, 330-7	36.3	303
116	CONSERTING: integrating copy-number analysis with structural-variation detection. *Nature Methods*, **2015**, 12, 527-30	21.6	56
115	Commutability of the First World Health Organization International Standard for Human Cytomegalovirus. *Journal of Clinical Microbiology*, **2015**, 53, 3325-33	9.7	62
114	MPTH-26MOLECULAR REFINEMENT OF PEDIATRIC POSTERIOR FOSSA EPENDYMOMA. *Neuro-Oncology*, **2015**, 17, v144.1-v144	1	78
113	SVSI: fast and powerful set-valued system identification approach to identifying rare variants in sequencing studies for ordered categorical traits. *Annals of Human Genetics*, **2015**, 79, 294-309	2.2	5
112	The methylome of pediatric acute myeloid leukemia.. *Journal of Clinical Oncology*, **2015**, 33, 10027-10027	2.2	
111	Methylation of DNMT3B Strongly Associates with the Methylome, Cytogenetic Risk Groups, and Prognosis of Pediatric Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2434-2434	2.2	

110	MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients. *Frontiers in Pharmacology*, **2015**, 6, 324	5.6	12
109	Definition of cure in childhood acute myeloid leukemia. *Cancer*, **2014**, 120, 2490-6	6.4	10
108	A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. *American Journal of Hematology*, **2014**, 89, 889-95	7.1	68
107	The most informative spacing test effectively discovers biologically relevant outliers or multiple modes in expression. *Bioinformatics*, **2014**, 30, 1400-8	7.2	8
106	An R package that automatically collects and archives details for reproducible computing. *BMC Bioinformatics*, **2014**, 15, 138	3.6	11
105	The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. *Nature Genetics*, **2014**, 46, 444-450	36.3	659
104	A new system identification approach to identify genetic variants in sequencing studies for a binary phenotype. *Human Heredity*, **2014**, 78, 104-16	1.1	13
103	A Conditional Approach for Regression Analysis of Longitudinal Data with Informative Observation Time and Non-negligible Observation Duration. *Communications in Statistics - Theory and Methods*, **2014**, 43, 4998-5011	0.5	1
102	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. *Cancer*, **2014**, 120, 1985-92	6.4	40
101	RB1 gene inactivation by chromothripsis in human retinoblastoma. *Oncotarget*, **2014**, 5, 438-50	3.3	77
100	High-Throughput, High-Content siRNA/Drug Modifier Screen for Validation of Transcriptional Profiles Predictive of Cytarabine Response in AML. *Blood*, **2014**, 124, 3615-3615	2.2	
99	Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. *Cancer*, **2013**, 119, 4036-43	6.4	31
98	Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. *Journal of Clinical Microbiology*, **2013**, 51, 540-6	9.7	233
97	Joint analysis of longitudinal data and recurrent episodes data with application to medical cost analysis. *Biometrical Journal*, **2013**, 55, 5-16	1.5	5
96	Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421. *Leukemia*, **2013**, 27, 731-4	10.7	31
95	Comparison of two multiplexed PCR assays for the detection of HSV-1, HSV-2, and VZV with extracted and unextracted cutaneous and mucosal specimens. *Journal of Clinical Virology*, **2013**, 58, 84-8	14.5	15
94	A genomic random interval model for statistical analysis of genomic lesion data. *Bioinformatics*, **2013**, 29, 2088-95	7.2	13
93	PAIR: paired allelic log-intensity-ratio-based normalization method for SNP-CGH arrays. *Bioinformatics*, **2013**, 29, 299-307	7.2	6

92	Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. *Clinical Cancer Research*, **2013**, 19, 1620-7	12.9	41
91	RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. *Pharmacogenomics*, **2013**, 14, 1449-66	2.6	21
90	An empirical Bayes approach for analysis of diverse periodic trends in time-course gene expression data. *Bioinformatics*, **2013**, 29, 182-8	7.2	3
89	Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. *Blood*, **2013**, 121, 4366-76	2.2	36
88	Cross-species genomic and epigenomic landscape of retinoblastoma. *Oncotarget*, **2013**, 4, 844-59	3.3	34
87	Statistical Methods for Overdispersion in mRNA-Seq Count Data. *Open Bioinformatics Journal*, **2013** , 7, 34-40	0.8	3
86	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. *Blood*, **2012**, 119, e67-75	2.2	59
85	An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. *Cancer Cell*, **2012**, 22, 683-97	24.3	161
84	Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. *Journal of Clinical Oncology*, **2012**, 30, 3625-32	2.2	151
83	High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. *Blood*, **2012**, 120, 4783-94	2.2	156
82	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature*, **2012**, 481, 157-63	50.4	1163
81	A novel retinoblastoma therapy from genomic and epigenetic analyses. *Nature*, **2012**, 481, 329-34	50.4	364
80	Novel mutations target distinct subgroups of medulloblastoma. *Nature*, **2012**, 488, 43-8	50.4	590
79	Effect of body mass index on the outcome of children with acute myeloid leukemia. *Cancer*, **2012**, 118, 5989-96	6.4	44
78	Treatment outcome in older patients with childhood acute myeloid leukemia. *Cancer*, **2012**, 118, 6253-9	6.4	28
77	A mouse model of the most aggressive subgroup of human medulloblastoma. *Cancer Cell*, **2012**, 21, 168-80	24.3	208
76	Empirical bayesian selection of hypothesis testing procedures for analysis of sequence count expression data. *Statistical Applications in Genetics and Molecular Biology*, **2012**, 11,	1.2	9
75	Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. *PLoS ONE*, **2012**, 7, e42739	3.7	59

74	Cytarabine-Induced Gene Expression Signatures in AML Patients and Its Association with Clinical Outcome.. *Blood*, **2012**, 120, 2470-2470	2.2	
73	Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. *International Journal of Data Mining and Bioinformatics*, **2011**, 5, 143-57	0.5	11
72	Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. *Leukemia*, **2011**, 25, 1354-6	10.7	14
71	Regression analysis of longitudinal data with informative observation times and application to medical cost data. *Statistics in Medicine*, **2011**, 30, 1429-40	2.3	6
70	Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. *Cancer*, **2011**, 117, 1313-20	6.4	11
69	Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. *Pharmacogenomics*, **2011**, 12, 327-39	2.6	21
68	IDH1 and IDH2 mutations in pediatric acute leukemia. *Leukemia*, **2011**, 25, 1570-7	10.7	62
67	Genetic variants in cytosolic 5Snucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 339, 9-23	4.7	37
66	Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. *Journal of Clinical Oncology*, **2011**, 29, 3293-300	2.2	124
65	Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. *Journal of the National Cancer Institute*, **2011**, 103, 893-905	9.7	45
64	A procedure to statistically evaluate agreement of differential expression for cross-species genomics. *Bioinformatics*, **2011**, 27, 2098-103	7.2	11
63	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Childrens Research Hospital - Washington University Pediatric Cancer Genome Project. *Blood*, **2011**, 118, 68-68	2.2	
62	Cross-species genomics matches driver mutations and cell compartments to model ependymoma. *Nature*, **2010**, 466, 632-6	50.4	283
61	Subtypes of medulloblastoma have distinct developmental origins. *Nature*, **2010**, 468, 1095-9	50.4	590
60	NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. *Journal of Clinical Oncology*, **2010**, 28, 955-9	2.2	458
59	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. *Lancet Oncology, The*, **2010**, 11, 543-52	21.7	432
58	Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. *Cancer*, **2010**, 116, 98-105	6.4	20
57	ChIP-PaM: an algorithm to identify protein-DNA interaction using ChIP-Seq data. *Theoretical Biology and Medical Modelling*, **2010**, 7, 18	2.3	16

56	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. *Blood*, **2010**, 116, 1073-1073	2.2	1
55	Pathway Based Pharmacogenomics of Cytarabine In Pediatric Acute Myeloid Leukemia. *Blood*, **2010**, 116, 294-294	2.2	
54	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. *Blood*, **2010**, 116, 849-849	2.2	
53	IDH1 and IDH2 Mutations In Pediatric Acute Myeloid Leukemia. *Blood*, **2010**, 116, 1699-1699	2.2	
52	Reference alignment of SNP microarray signals for copy number analysis of tumors. *Bioinformatics*, **2009**, 25, 315-21	7.2	52
51	Integrated Analysis of Pharmacokinetic, Clinical, and SNP Microarray Data Using Projection onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing **2009**,		1
50	Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 12944-9	11.5	143
49	Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. *JAMA - Journal of the American Medical Association*, **2009**, 301, 393-403	27.4	174
48	PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. *Bioinformatics*, **2009**, 25, 2013-9	7.2	14
47	Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. *Leukemia*, **2009**, 23, 402-4	10.7	29
46	Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. *Leukemia*, **2009**, 23, 1410-6	10.7	44
45	The Beta-Binomial Distribution for Estimating the Number of False Rejections in Microarray Gene Expression Studies. *Computational Statistics and Data Analysis*, **2009**, 53, 1688-1700	1.6	3
44	Assumption Adequacy Averaging as a Concept to Develop More Robust Methods for Differential Gene Expression Analysis. *Computational Statistics and Data Analysis*, **2009**, 53, 1604-1612	1.6	8
43	Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. *Blood*, **2009**, 113, 5083-9	2.2	135
42	Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome.. *Blood*, **2009**, 114, 482-482	2.2	2
41	Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 114-114	2.2	1
40	Minimal Residual Disease-Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.. *Blood*, **2009**, 114, 16-16	2.2	
39	5'-Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 593-593	2.2	

38	Robust detection method for differential expression studies. *BMC Bioinformatics*, **2008**, 9,	3.6	78
37	Statistical analysis of data from retroviral clonal experiments in the developing retina. *Brain Research*, **2008**, 1192, 178-85	3.7	5
36	Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus. *Journal of Clinical Microbiology*, **2008**, 46, 157-63	9.7	107
35	N-myc coordinates retinal growth with eye size during mouse development. *Genes and Development*, **2008**, 22, 179-93	12.6	39
34	Identification of clinical coryneform bacterial isolates: comparison of biochemical methods and sequence analysis of 16S rRNA and rpoB genes. *Journal of Clinical Microbiology*, **2008**, 46, 921-7	9.7	32
33	Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. *Pediatric Infectious Disease Journal*, **2008**, 27, 815-9	3.4	62
32	Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia. *Pediatric Blood and Cancer*, **2008**, 50, 542-8	3	1
31	Baseline mannose binding lectin levels may not predict infection among children with leukemia. *Pediatric Blood and Cancer*, **2008**, 50, 866-8	3	9
30	Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. *Cancer*, **2008**, 113, 376-82	6.4	82
29	Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. *Cancer*, **2008**, 113, 522-9	6.4	68
28	Gene Expression Profiling of Acute Myeloid Leukemia Shows Therapeutically Meaningful Patterns of Association with Ara-CTP Pharmacokinetics and Pharmacodynamics. *Blood*, **2008**, 112, 215-215	2.2	
27	Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. *Cancer*, **2007**, 109, 157-63	6.4	71
26	Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience. *Pediatric Blood and Cancer*, **2007**, 48, 10-5	3	43
25	Genome scan implicates adhesion biological pathways in secondary leukemia. *Leukemia*, **2007**, 21, 2128-36	10.7	22
24	Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature*, **2007**, 446, 758-64	30.4	1398
23	Gene expression profiling of childhood adrenocortical tumors. *Cancer Research*, **2007**, 67, 600-8	10.1	127
22	Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 323, 935-45	4.7	70
21	Persistent hyperplastic primary vitreous due to somatic mosaic deletion of the arf tumor suppressor. *Investigative Ophthalmology and Visual Science*, **2007**, 48, 491-9		28

20	Quantitative real-time PCR detection of adenovirus in clinical blood specimens: a comparison of plasma, whole blood and peripheral blood mononuclear cells. *Journal of Clinical Virology*, **2007**, 40, 295-300	14.5	18
19	False discovery rate paradigms for statistical analyses of microarray gene expression data. *Bioinformation*, **2007**, 1, 436-46	1.1	29
18	Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. *Cancer*, **2006**, 106, 2495-502	6.4	47
17	Robust estimation of the false discovery rate. *Bioinformatics*, **2006**, 22, 1979-87	7.2	126
16	Estimation and control of multiple testing error rates for microarray studies. *Briefings in Bioinformatics*, **2006**, 7, 25-36	13.4	67
15	Filtration-based culture methods improve recovery of fungal pathogens in respiratory specimens. *Diagnostic Microbiology and Infectious Disease*, **2006**, 56, 221-3	2.9	1
14	Genes Regulating B-Cell Development and Differentiation Are Mutated in 40% of Pediatric Acute Lymphoblastic Leukemia.. *Blood*, **2006**, 108, 217-217	2.2	
13	Statistical development and evaluation of microarray gene expression data filters. *Journal of Computational Biology*, **2005**, 12, 482-95	1.7	27
12	Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. *British Journal of Haematology*, **2005**, 130, 781-7	4.5	67
11	Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. *Leukemia*, **2005**, 19, 2125-9	10.7	45
10	Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. *Arthritis and Rheumatism*, **2005**, 52, 865-76		67
9	Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. *Pediatric Blood and Cancer*, **2005**, 44, 63-9	3	30
8	Sample size determination for the false discovery rate. *Bioinformatics*, **2005**, 21, 4263-71	7.2	50
7	Outcome after Relapse of Childhood Acute Myeloid Leukemia: The St. Jude Experience.. *Blood*, **2005**, 106, 273-273	2.2	
6	Statistical significance threshold criteria for analysis of microarray gene expression data. *Statistical Applications in Genetics and Molecular Biology*, **2004**, 3, Article36	1.2	30
5	Improving false discovery rate estimation. *Bioinformatics*, **2004**, 20, 1737-45	7.2	114
4	Gene expression profiling of pediatric acute myelogenous leukemia. *Blood*, **2004**, 104, 3679-87	2.2	357
3	Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. *British Journal of Haematology*, **2003**, 123, 243-52	4.5	107

2	Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. *Bioinformatics*, **2003**, 19, 1236-42	7.2	309
1	Estimating the fraction of clonable genomic DNA. *Bulletin of Mathematical Biology*, **2001**, 63, 995-1002	2.1	1